Diagnostic Utility of Galectin-3 in Thyroid Cancer

Gharib, 2007, Thyroid nodules: clinical importance, assessment, and treatment, Endocrinol Metab Clin North Am, 36, 707, 10.1016/j.ecl.2007.04.009 Gharib, 1994, Fine-needle aspiration biopsy of thyroid nodules: advantages, limitations, and effect, Mayo Clin Proc, 69, 44, 10.1016/S0025-6196(12)61611-5 Wiseman, 2006, Hemithyroidectomy: the optimal initial surgical approach for individuals undergoing surgery for a cytological diagnosis of follicular neoplasm, Ann Surg Oncol, 13, 425, 10.1245/ASO.2006.03.089 Melck, 2006, Hemithyroidectomy: the preferred initial surgical approach for management of Hurthle cell neoplasm, Am J Surg, 191, 593, 10.1016/j.amjsurg.2006.02.007 Cooper, 2006, Management guidelines for patients with thyroid nodules and differentiated thyroid cancer, Thyroid, 16, 109, 10.1089/thy.2006.16.109 Wiseman, 2008, Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis, Ann Surg Oncol, 15, 2811, 10.1245/s10434-008-0034-8 Barondes, 1994, Galectins: a family of animal beta-galactoside-binding lectins, Cell, 76, 597, 10.1016/0092-8674(94)90498-7 Hsu, 1992, Biochemical and biophysical characterization of human recombinant IgE-binding protein, an S-type animal lectin, J Biol Chem, 267, 14167, 10.1016/S0021-9258(19)49693-2 Mehul, 1995, Cross-linking of galectin 3, a galactose-binding protein of mammalian cells, by tissue-type transglutaminase, FEBS Lett, 360, 160, 10.1016/0014-5793(95)00100-N Ahmad, 2004, Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes, J Biol Chem, 279, 10841, 10.1074/jbc.M312834200 Liu, 2005, Galectins as modulators of tumour progression, Nat Rev Cancer, 5, 29, 10.1038/nrc1527 Dumic, 2006, Galectin-3: an open-ended story, Biochim Biophys Acta, 1760, 616, 10.1016/j.bbagen.2005.12.020 Ramasamy, 2007, The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop, Mol Cell, 27, 992, 10.1016/j.molcel.2007.07.031 Nieminen, 2007, Visualization of galectin-3 oligomerization on the surface of neutrophils and endothelial cells using fluorescence resonance energy transfer, J Biol Chem, 282, 1374, 10.1074/jbc.M604506200 Partridge, 2004, Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis, Science, 306, 120, 10.1126/science.1102109 Lajoie, 2007, Plasma membrane domain organization regulates EGFR signaling in tumor cells, J Cell Biol, 179, 341, 10.1083/jcb.200611106 Gong, 1999, The NH2 terminus of galectin-3 governs cellular compartmentalization and functions in cancer cells, Cancer Res, 59, 6239 Xu, 1995, Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications, Am J Pathol, 147, 815 Yang, 1996, Expression of galectin-3 modulates T-cell growth and apoptosis, Proc Natl Acad Sci USA, 93, 6737, 10.1073/pnas.93.13.6737 Paron, 2003, Nuclear localization of Galectin-3 in transformed thyroid cells: a role in transcriptional regulation, Biochem Biophys Res Commun, 302, 545, 10.1016/S0006-291X(03)00151-7 Lin, 2009, Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells, Biochem Biophys Res Commun, 379, 626, 10.1016/j.bbrc.2008.12.153 Shi, 2007, Inhibition of Wnt-2 and galectin-3 synergistically destabilizes beta-catenin and induces apoptosis in human colorectal cancer cells, Int J Cancer, 121, 1175, 10.1002/ijc.22848 Akahani, 1997, Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family, Cancer Res, 57, 5272 Yu, 2002, Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation, J Biol Chem, 277, 15819, 10.1074/jbc.M200154200 Cecchinelli, 2006, Repression of the antiapoptotic molecule galectin-3 by homeodomain-interacting protein kinase 2-activated p53 is required for p53-induced apoptosis, Mol Cell Biol, 26, 4746, 10.1128/MCB.00959-05 Lavra, 2009, Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas, J Pathol, 218, 66, 10.1002/path.2510 Fukumori, 2004, Endogenous galectin-3 determines the routing of CD95 apoptotic signaling pathways, Cancer Res, 64, 3376, 10.1158/0008-5472.CAN-04-0336 Liu, 2004, Nucling mediates apoptosis by inhibiting expression of galectin-3 through interference with nuclear factor kappaB signalling, Biochem J, 380, 31, 10.1042/bj20031300 Takenaka, 2003, Malignant transformation of thyroid follicular cells by galectin-3, Cancer Lett, 195, 111, 10.1016/S0304-3835(03)00056-9 Bresalier, 1998, Metastasis of human colon cancer is altered by modifying expression of the beta-galactoside-binding protein galectin 3, Gastroenterology, 115, 287, 10.1016/S0016-5085(98)70195-7 van den Brule, 2004, Expression of galectins in cancer: a critical review, Glycoconj J, 19, 537, 10.1023/B:GLYC.0000014083.48508.6a Davidson, 2002, Shuttling of galectin-3 between the nucleus and cytoplasm, Glycobiology, 12, 329, 10.1093/glycob/12.5.329 Yoshii, 2002, Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest, J Biol Chem, 277, 6852, 10.1074/jbc.M107668200 Takenaka, 2004, Galectin-3 and metastasis, Glycoconj J, 19, 543, 10.1023/B:GLYC.0000014084.01324.15 Califice, 2004, Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3, Oncogene, 23, 7527, 10.1038/sj.onc.1207997 Dennis, 1989, Oncodevelopmental expression of–GlcNAc beta 1–6Man alpha 1–6Man beta 1–branched asparagine-linked oligosaccharides in murine tissues and human breast carcinomas, Cancer Res, 49, 945 Miyoshi, 1995, Transforming growth factor beta up-regulates expression of the N-acetylglucosaminyltransferase V gene in mouse melanoma cells, J Biol Chem, 270, 6216, 10.1074/jbc.270.11.6216 Yao, 1998, Elevated activity of N-acetylglucosaminyltransferase V in human hepatocellular carcinoma, J Cancer Res Clin Oncol, 124, 27, 10.1007/s004320050129 Murata, 2000, Expression of N-acetylglucosaminyltransferase V in colorectal cancer correlates with metastasis and poor prognosis, Clin Cancer Res, 6, 1772 Fernandes, 1991, Beta 1-6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia, Cancer Res, 51, 718 Granovsky, 2000, Suppression of tumor growth and metastasis in Mgat5-deficient mice, Nat Med, 6, 306, 10.1038/73163 Lau, 2007, Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation, Cell, 129, 123, 10.1016/j.cell.2007.01.049 Lagana, 2006, Galectin binding to Mgat5-modified N-glycans regulates fibronectin matrix remodeling in tumor cells, Mol Cell Biol, 26, 3181, 10.1128/MCB.26.8.3181-3193.2006 Goetz, 2008, Concerted regulation of focal adhesion dynamics by galectin-3 and tyrosine-phosphorylated caveolin-1, J Cell Biol, 180, 1261, 10.1083/jcb.200709019 Dennis, 2009, Adaptive regulation at the cell surface by N-glycosylation, Traffic, 10, 1569, 10.1111/j.1600-0854.2009.00981.x Lajoie, 2009, Lattices, rafts, and scaffolds: domain regulation of receptor signaling at the plasma membrane, J Cell Biol, 185, 381, 10.1083/jcb.200811059 Griffith, 2008, Biomarker panel diagnosis of thyroid cancer: a critical review, Expert Rev Anticancer Ther, 8, 1399, 10.1586/14737140.8.9.1399 Orlandi, 1998, Galectin-3 is a presurgical marker of human thyroid carcinoma, Cancer Res, 58, 3015 Gasbarri, 1999, Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules, J Clin Oncol, 17, 3494, 10.1200/JCO.1999.17.11.3494 Inohara, 1999, Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms, Cancer, 85, 2475, 10.1002/(SICI)1097-0142(19990601)85:11<2475::AID-CNCR25>3.0.CO;2-1 Bartolazzi, 2001, Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions, Lancet, 357, 1644, 10.1016/S0140-6736(00)04817-0 Saggiorato, 2001, Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma, J Clin Endocrinol Metab, 86, 5152, 10.1210/jcem.86.11.8043 Aratake, 2002, Diagnostic utility of galectin-3 and CD26/DPPIV as preoperative diagnostic markers for thyroid nodules, Diagn Cytopathol, 26, 366, 10.1002/dc.10111 Papotti, 2002, Role of galectin-3 immunodetection in the cytological diagnosis of thyroid cystic papillary carcinoma, Eur J Endocrinol, 147, 515, 10.1530/eje.0.1470515 Maruta, 2004, Immunostaining of galectin-3 and CD44v6 using fine-needle aspiration for distinguishing follicular carcinoma from adenoma, Diagn Cytopathol, 31, 392, 10.1002/dc.20156 Saggiorato, 2004, Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas, J Endocrinol Invest, 27, 311, 10.1007/BF03351054 Collet, 2005, Galectin-3 immunodetection in follicular thyroid neoplasms: a prospective study on fine-needle aspiration samples, Br J Cancer, 93, 1175, 10.1038/sj.bjc.6602822 Mills, 2005, Galectin-3 is not useful in thyroid FNA, Cytopathology, 16, 132, 10.1111/j.1365-2303.2005.00213.x Saggiorato, 2005, Characterization of thyroid ‘follicular neoplasms’ in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application, Endocr Relat Cancer, 12, 305, 10.1677/erc.1.00944 Aron, 2006, Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms, Indian J Pathol Microbiol, 49, 376 Carpi, 2006, Large needle aspiration biopsy and galectin-3 determination in selected thyroid nodules with indeterminate FNA-cytology, Br J Cancer, 95, 204, 10.1038/sj.bjc.6603232 Kim, 2006, Diagnostic utility of galectin-3 in aspirates of thyroid follicular lesions, Acta Cytol, 50, 28, 10.1159/000325891 Torres-Cabala, 2006, Proteomic identification of new biomarkers and application in thyroid cytology, Acta Cytol, 50, 518, 10.1159/000326006 Sapio, 2007, Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma, Endocr Relat Cancer, 14, 1089, 10.1677/ERC-07-0147 Hooft, 2008, Hexokinase III, cyclin A and galectin-3 are overexpressed in malignant follicular thyroid nodules, Clin Endocrinol (Oxf), 68, 252, 10.1111/j.1365-2265.2007.03031.x Ersoz, 2008, The significance of Galectin-3 expression in the immunocytochemical evaluation of thyroid fine needle aspiration cytology, Pathol Oncol Res, 14, 457, 10.1007/s12253-008-9041-0 Bartolazzi, 2008, Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study, Lancet Oncol, 9, 543, 10.1016/S1470-2045(08)70132-3 Franco, 2009, Molecular markers in thyroid fine-needle aspiration biopsy: a prospective study, Appl Immunohistochem Mol Morphol, 17, 211, 10.1097/PAI.0b013e31818935a9 Fernandez, 1997, Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue, J Pathol, 181, 80, 10.1002/(SICI)1096-9896(199701)181:1<80::AID-PATH699>3.0.CO;2-E Cvejic, 2000, Galectin-3 and carcinoembryonic antigen expression in medullary thyroid carcinoma: possible relation to tumour progression, Histopathology, 37, 530, 10.1046/j.1365-2559.2000.00988.x Kawachi, 2000, Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation, Hum Pathol, 31, 428, 10.1053/hp.2000.6534 Nascimento, 2001, Differential reactivity for galectin-3 in Hurthle cell adenomas and carcinomas, Endocr Pathol, 12, 275, 10.1385/EP:12:3:275 Beesley, 2002, Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules, Histopathology, 41, 236, 10.1046/j.1365-2559.2002.01442.x Coli, 2002, Galectin-3, a marker of well-differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia, Histopathology, 40, 80, 10.1046/j.1365-2559.2002.01304.x Faggiano, 2002, Differential expression of galectin-3 in medullary thyroid carcinoma and C-cell hyperplasia, Clin Endocrinol (Oxf), 57, 813, 10.1046/j.1365-2265.2002.01673.x Herrmann, 2002, Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions, Arch Pathol Lab Med, 126, 710, 10.5858/2002-126-0710-IEOGIB Casey, 2003, Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1, Endocr Pathol, 14, 55, 10.1385/EP:14:1:55 Feilchenfeldt, 2003, Expression of galectin-3 in normal and malignant thyroid tissue by quantitative PCR and immunohistochemistry, Mod Pathol, 16, 1117, 10.1097/01.MP.0000096047.99202.31 Giannini, 2003, Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens, Thyroid, 13, 765, 10.1089/105072503768499662 Kovacs, 2003, The investigation of galectin-3 in diseases of the thyroid gland, Eur J Endocrinol, 149, 449, 10.1530/eje.0.1490449 Mehrotra, 2004, Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms, Histopathology, 45, 493, 10.1111/j.1365-2559.2004.01978.x Oestreicher-Kedem, 2004, Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions, Head Neck, 26, 960, 10.1002/hed.20087 Weber, 2004, The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer, Am J Clin Pathol, 122, 524, 10.1309/UUQTE505PTN5QJ7M de Matos, 2005, Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy, Histopathology, 47, 391, 10.1111/j.1365-2559.2005.02221.x Ito, 2005, Galectin-3 expression in follicular tumours: an immunohistochemical study of its use as a marker of follicular carcinoma, Pathology, 37, 296, 10.1080/00313020500169545 Nucera, 2005, Human galectin-3 immunoexpression in thyroid follicular adenomas with cell atypia, J Endocrinol Invest, 28, 106, 10.1007/BF03345351 Prasad, 2005, Galectin-3, fibronectin-1. CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors, Mod Pathol, 18, 48, 10.1038/modpathol.3800235 Cvejic, 2005, Galectin-3 expression in papillary thyroid carcinoma: relation to histomorphologic growth pattern, lymph node metastasis, extrathyroid invasion, and tumor size, Head Neck, 27, 1049, 10.1002/hed.20276 Cvejic, 2005, Galectin-3 and proliferating cell nuclear antigen (PCNA) expression in papillary thyroid carcinoma, Exp Oncol, 27, 210 Aratake, 2006, Coexistent anaplastic and differentiated thyroid carcinoma: an immunohistochemical study, Am J Clin Pathol, 125, 399, 10.1309/LF3Q1NQKMT2N9KNV Barroeta, 2006, Diagnostic value of differential expression of CK19. Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis, Endocr Pathol, 17, 225, 10.1385/EP:17:3:225 Nakamura, 2006, Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma, Endocr Pathol, 17, 213, 10.1385/EP:17:3:213 Rossi, 2006, Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid, Histopathology, 48, 795, 10.1111/j.1365-2559.2006.02428.x Scognamiglio, 2006, Diagnostic usefulness of HBME1, galectin-3. CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma, Am J Clin Pathol, 126, 700, 10.1309/044V86JN2W3CN5YB Coli, 2007, Atypical thyroid nodules express both HBME-1 and Galectin-3, two phenotypic markers of papillary thyroid carcinoma, J Exp Clin Cancer Res, 26, 221 Park, 2007, Diagnostic value of galectin-3. HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules, J Korean Med Sci, 22, 621, 10.3346/jkms.2007.22.4.621 Pulcrano, 2007, Poorly differentiated follicular thyroid carcinoma: prognostic factors and relevance of histological classification, Thyroid, 17, 639, 10.1089/thy.2007.0029 Torregrossa, 2007, Galectin-3 is highly expressed in nonencapsulated papillary thyroid carcinoma but weakly expressed in encapsulated type; comparison with Hector Battifora mesothelial cell 1 immunoreactivity, Hum Pathol, 38, 1482, 10.1016/j.humpath.2007.02.013 Viacava, 2007, Markers of cell proliferation, apoptosis, and angiogenesis in thyroid adenomas: a comparative immunohistochemical and genetic investigation of functioning and nonfunctioning nodules, Thyroid, 17, 191, 10.1089/thy.2006.0175 Weinberger, 2007, Association of nuclear, cytoplasmic expression of galectin-3 with beta-catenin/Wnt-pathway activation in thyroid carcinoma, Arch Otolaryngol Head Neck Surg, 133, 503, 10.1001/archotol.133.5.503 Liu, 2008, Eur J Endocrinol, 158, 375, 10.1530/EJE-07-0492 Londero, 2007, Papillary microcarcinoma of the thyroid gland: is the immunohistochemical expression of cyclin D1 or galectin-3 in primary tumour an indicator of metastatic disease?, Acta Oncol, 1 Murphy, 2008, Identification of immunohistochemical biomarkers for papillary thyroid carcinoma using gene expression profiling, Hum Pathol, 39, 420, 10.1016/j.humpath.2007.07.015 Savin, 2008, Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation, Hum Pathol, 39, 1656, 10.1016/j.humpath.2008.04.006 Inohara, 2008, Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies, Biochem Biophys Res Commun, 376, 605, 10.1016/j.bbrc.2008.09.041 Kashima, 1997, Cytoplasmic biotin-like activity interferes with immunohistochemical analysis of thyroid lesions: a comparison of antigen retrieval methods, Mod Pathol, 10, 515 Kim, 2002, The enhanced reactivity of endogenous biotin-like molecules by antigen retrieval procedures and signal amplification with tyramine, Histochem J, 34, 97, 10.1023/A:1020954611464 Bussolati, 1997, Retrieved endogenous biotin: a novel marker and a potential pitfall in diagnostic immunohistochemistry, Histopathology, 31, 400, 10.1046/j.1365-2559.1997.3020895.x Baloch, 2008, Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference, Diagn Cytopathol, 36, 425, 10.1002/dc.20830 Raphael, 2002, The meanings of markers: ancillary techniques in diagnosis of thyroid neoplasia, Endocr Pathol, 13, 301, 10.1385/EP:13:4:301 Carlson, 2006, HER2 testing in breast cancer: NCCN Task Force report and recommendations, J Natl Compr Canc Netw, 4, S1 Fowler, 2008, Application of immunohistochemistry to cytology, Arch Pathol Lab Med, 132, 373, 10.5858/2008-132-373-AOITC Carpi, 2007, Percutaneous large-needle aspiration biopsy histology of palpable thyroid nodules: technical and diagnostic performance, Histopathology, 51, 249, 10.1111/j.1365-2559.2007.02764.x Pazaitou-Panayiotou, 2007, Clinical features and therapeutic implication of papillary thyroid microcarcinoma, Thyroid, 17, 1085, 10.1089/thy.2007.0005 Noguchi, 2008, Papillary microcarcinoma, World J Surg, 32, 747, 10.1007/s00268-007-9453-0 Cvejic, 2005, Galectin-3 expression in papillary microcarcinoma of the thyroid, Histopathology, 47, 209, 10.1111/j.1365-2559.2005.02199.x Berho, 1995, Clear nuclear changes in Hashimoto's thyroiditis. A clinicopathologic study of 12 cases, Ann Clin Lab Sci, 25, 513 Prasad, 2004, Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC, Histopathology, 45, 39, 10.1111/j.1365-2559.2004.01876.x Wiseman, 2007, Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma, Arch Surg, 142, 717, 10.1001/archsurg.142.8.717 Griffith, 2006, Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers, J Clin Oncol, 24, 5043, 10.1200/JCO.2006.06.7330 Finley, 2004, Discrimination of benign and malignant thyroid nodules by molecular profiling, Ann Surg, 240, 425, 10.1097/01.sla.0000137128.64978.bc Huang, 2001, Gene expression in papillary thyroid carcinoma reveals highly consistent profiles, Proc Natl Acad Sci USA, 98, 15044, 10.1073/pnas.251547398 Jarzab, 2005, Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications, Cancer Res, 65, 1587, 10.1158/0008-5472.CAN-04-3078 Finn, 2007, Expression microarray analysis of papillary thyroid carcinoma and benign thyroid tissue: emphasis on the follicular variant and potential markers of malignancy, Virchows Arch, 450, 249, 10.1007/s00428-006-0348-5 Lubitz, 2006, Microarray analysis of thyroid nodule fine-needle aspirates accurately classifies benign and malignant lesions, J Mol Diagn, 8, 490, 10.2353/jmoldx.2006.060080 Lubitz, 2005, Molecular analysis of minimally invasive follicular carcinomas by gene profiling, Surgery, 138, 1042, 10.1016/j.surg.2005.09.009 Martins, 2002, Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors, J Clin Endocrinol Metab, 87, 4806, 10.1210/jc.2002-020094 Bernet, 2002, Determination of galectin-3 messenger ribonucleic Acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction, J Clin Endocrinol Metab, 87, 4792, 10.1210/jc.2002-020390 Takano, 2003, Ubiquitous expression of galectin-3 mRNA in benign and malignant thyroid tumors, Cancer Lett, 199, 69, 10.1016/S0304-3835(03)00343-4 Takano, 2005, Decreased relative expression level of trefoil factor 3 mRNA to galectin-3 mRNA distinguishes thyroid follicular carcinoma from adenoma, Cancer Lett, 219, 91, 10.1016/j.canlet.2004.07.004 Pagedar, 2008, Molecular classification of thyroid nodules by cytology, Laryngoscope, 118, 692, 10.1097/MLG.0b013e31815ed0ff Bojunga, 2004, Molecular detection of thyroid cancer: an update, Clin Endocrinol (Oxf), 61, 523, 10.1111/j.1365-2265.2004.02131.x Saussez, 2008, Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease, Thyroid, 18, 705, 10.1089/thy.2007.0361 Iurisci, 2009, Synthetic inhibitors of galectin-1 and -3 selectively modulate homotypic cell aggregation and tumor cell apoptosis, Anticancer Res, 29, 403 Bartolazzi, 2008, Thyroid cancer imaging in vivo by targeting the anti-apoptotic molecule galectin-3, PLoS One, 3, e3768, 10.1371/journal.pone.0003768